Novo Nordisk's Wegovy helps 40% of young children lose enough weight to no longer be obese in trial
In a late-stage trial, 40.4% of children aged 6 to under 12 treated with semaglutide (Wegovy's active ingredient) were no longer obese after treatment, compared to the control group.
